Long-term safety and efficacy of lasmiditan for acute treatment of migraine: Final results of the GLADIATOR study

• Autores principales: Jan Lewis Brandes (Autor), Suzanne Klise (Autor), John H Krege (Autor), Michael Case (Autor), Rashna Khanna (Autor), Raghavendra Vasudeva (Autor), Joel Raskin (Autor), David Kudrow (Autor)
• Formato: Libro
• Publicado: SAGE Publishing, 2020-09-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

GLADIATOR was a prospective, randomized, open-label, phase 3 study of lasmiditan 100 mg or 200 mg dosed intermittently for up to 1 year in patients with episodic migraine. Most patients had completed one of two single-attack studies before participation. A total of 2030 patients received ≥1 lasmidit...